Christophe WEBER,
President Designate, GSK Biologicals
Innovation is key in healthcare and GSK is a leader today thanks to two main factors. Our workforce is passionate, committed and proud of its contribution to healthcare throughout the world. Developing vaccines with unique qualities, challenging more diseases, improving the efficacy of current vaccines, inventing new ways of achieving our goals so that vaccines are made available as quickly and as widely as possible and daring to take radically different path from the competition are principles which made us into a leading player. We are sure that the ESSEC Chair of Therapeutic Innovation will reinforce our talent development thanks to its objective to train the future decision makers of the health industry in innovation management. The second factor is partnership. Scientific, academic and economic partnership underpinning the activities of GSK Biologicals. The quality and range of its vaccines are the fruit of an approach that is based on the sharing of information and expertise, both internal as external. We are more than delighted to be involved in the ESSEC Chair of Therapeutic Innovation and we are convinced that its expertise, its unique learning model as well as the programme it offers will constitute a network of ideas on the managerial challenges in the health industry.
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s vaccines business, is one of the world’s leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development - both in the prophylactic and therapeutic fields. Headquartered in Belgium, with 13,000 employees worldwide inc 7,500 in Belgium, GSK Biologicals has 15 manufacturing sites strategically positioned around the globe. In 2010, GSK Biologicals distributed 1.4 billion doses of vaccines to 179 countries in both the developed and the developing world. GSK Biologicals is the only company to work simultaneously on the three WHO priority diseases - AIDS, Tuberculosis and Malaria - and is a key supplier of international organisations such as GAVI or UNICEF, and collaborates with country decision-makers to develop vaccination policies and to ensure that the vaccines are available for everyone.
Partners
Brochure
Yearbook